Ohgitani S, Fujita T
Division of Laboratory and Research, National Sanatorium Hyogo Chuo Hospital, Sanda, Japan.
J Bone Miner Metab. 2000;18(5):283-6. doi: 10.1007/pl00010643.
In nine normal subjects, four men and five women between 23 and 49 years of age, 800mg calcium was orally administered as active absorbable algal calcium (AAA Ca) (A) and calcium carbonate (CaCO3) (B), to compare with non-calcium-containing placebo (C) in a crossover design. Calcium, oxalate, osmolality, creatinine, and pH were measured in the first three morning urine samples and Ca/osmolality, Ca/osmolality/body weight, Ca/creatinine, and oxalate/ osmolality were calculated to correct for urine dilution. Ca x oxalate product was also calculated, and Ca oxalate crystal in the sediment was microscopically examined, semiquantitatively estimated as -, +, ++, or , and numerically expressed as 0, 1, 2, or 3, respectively. Urinary Ca excretion was similar in groups A and B, but significantly larger than in group C, regardless of the method of correction for dilution. Urinary oxalate excretion with correction for osmolality, however, was significantly lower in A than in B and C, which gave similar values. Urine pH was similar among all three groups. Ca x oxalate product was significantly higher in C than in A, but A and B were not significantly different. AAA Ca appeared to decrease urinary oxalate excretion and Ca x oxalate product more efficiently than CaCO3, suggesting the possibility of inhibiting the formation of Ca x oxalate kidney stones.
在9名年龄在23至49岁之间的正常受试者(4名男性和5名女性)中,采用交叉设计,口服800毫克活性可吸收海藻钙(AAA钙)(A组)和碳酸钙(CaCO₃)(B组),并与不含钙的安慰剂(C组)进行比较。在前三个早晨的尿液样本中测量钙、草酸盐、渗透压、肌酐和pH值,并计算钙/渗透压、钙/渗透压/体重、钙/肌酐和草酸盐/渗透压,以校正尿液稀释。还计算了钙×草酸盐产物,并对沉淀物中的草酸钙晶体进行显微镜检查,半定量估计为-、+、++或+++,并分别以数字0、1、2或3表示。无论采用何种稀释校正方法,A组和B组的尿钙排泄量相似,但均显著高于C组。然而,校正渗透压后,A组的尿草酸盐排泄量显著低于B组和C组,而B组和C组的尿草酸盐排泄量相似。三组的尿液pH值相似。C组的钙×草酸盐产物显著高于A组,但A组和B组无显著差异。与碳酸钙相比,海藻钙似乎能更有效地降低尿草酸盐排泄量和钙×草酸盐产物,这表明海藻钙有可能抑制草酸钙肾结石的形成。